Reducer
Financial Software · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
124-128 City Road, London, Greater Londo...Phone Number
+44 2039704686Website
www.reducer.co.ukRevenue
<$5 MillionIndustry
About Reducer
Is Reducer your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Reducer launches new products
Reducer, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Reducer had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Reducer has new funding data
Website visits: Recent activity has been detected on your website
Check if Reducer has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Reducer is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Reducer
Earning: See what the market has to say on Reducer recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Reducer as Masked Content
Find 3 more new buyers
Compare Similar Companies to Reducer
Compare insights from companies similar to Reducer, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Reducer
Reducer Tech Stack
A closer look at the technologies used by Reducer
Reducer News & Media
Neovasc Announces German Reimbursement Renewal
VANCOUVER and MINNEAPOLIS, Feb. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. (“Neovasc” or “the Company”) (NASDAQ , TSX : NVCN) today announced the German Institute for the Hospital Remuneration System (“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023.Neovasc Announces Progress on COSIRA-II Clinical Trial
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced an update on the COSIRA-II Clinical Trial ("Trial") status. COSIRA-II is the U.S. Investigational Device Exemption ("IDE") pivotal clinical trial the Company is executing for the Neovasc Reducer™ ("Reducer") towards an approval decision for the device in the United States. The Trial will randomize approximately 380 patNeovasc Comments on European Heart Journal Publication
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 18, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that European Heart Journal - Case Reports has published an article titled, "Implantation of the Coronary Sinus Reducer for Refractory Angina due to Coronary Microvascular Dysfunction in the Context of Apical Hypertrophic Cardiomyopathy - a Case Report." The article is authored by Dr. Kevin Cheng, et al, at the NationaNeovasc Reducer Obtains U.S. Outpatient Reimbursement
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 8, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Centers for Medicare and Medicaid Services ("CMS") has assigned the Neovasc Reducer™ ("Reducer") implant procedure a new outpatient reimbursement code payment status indicator, enabling U.S. hospitals to be reimbursed for the device and implant procedure.Effective January 1, 2023, the implantation of the Reduce
Top Financial Software Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Reducer
We make it really easy for businesses to reduce their costs. Sign up in a few clicks and our system analyses data in your accounting platform. We identify what you are currently buying and how much you are paying. We then send you a report with any areas where you could save. It's cost management made simple.... Read More